HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma

Key Points • Low prelymphodepletion mHLA-DR correlates with older age, poorer ECOG performance status, higher tumor burden, and systemic inflammation.• Low prelymphodepletion mHLA-DR is associated with poorer duration of response and survival in LBCL treated with anti-CD19 CAR T cells.

[1]  M. Geyer,et al.  Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing , 2021, Molecular therapy. Methods & clinical development.

[2]  G. Salles,et al.  Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells , 2021, Clinical nuclear medicine.

[3]  M. Sadelain,et al.  Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy , 2021, Nature Reviews Immunology.

[4]  L. Argaud,et al.  Bicentric evaluation of stabilizing sampling tubes for assessment of monocyte HLA‐DR expression in clinical samples , 2021, medRxiv.

[5]  T. Rimmele,et al.  Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury* , 2021, medRxiv.

[6]  T. Rimmele,et al.  [Study of monocytic myeloid-derived suppressor cells and CD4 lymphopenia in septic shock-induced immunosuppression]. , 2021, Annales de Biologie Clinique.

[7]  D. Bracewell,et al.  Enriching leukapheresis improves T cell activation and transduction efficiency during CAR T processing , 2021, Molecular therapy. Methods & clinical development.

[8]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity , 2021, Nature Reviews Immunology.

[9]  John E. Mullinax,et al.  Tumor interferon signaling and suppressive myeloid cells associate with CAR T cell failure in large B cell lymphoma. , 2021, Blood.

[10]  M. Hedrick,et al.  A flow cytometric assay for HLA‐DR expression on monocytes validated as a biomarker for enrollment in sepsis clinical trials , 2021, Cytometry. Part B, Clinical cytometry.

[11]  O. Oluwole,et al.  Understanding and Managing Large B Cell Lymphoma Relapses after Chimeric Antigen Receptor T Cell Therapy , 2021 .

[12]  P. Merlet,et al.  Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma. , 2020, Blood advances.

[13]  G. Salles,et al.  Myc Expression and Tumor-Infiltrating T Cells Are Associated with Response in Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel in the Juliet Trial , 2020 .

[14]  D. Miklos,et al.  Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.

[15]  Michael R. Green,et al.  Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas , 2020, Nature Medicine.

[16]  A. Zelenetz,et al.  Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. , 2020, Blood advances.

[17]  Michael L. Wang,et al.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.

[18]  I. Yakoub-Agha,et al.  Monitoring CAR T‐cells using flow cytometry , 2020, Cytometry. Part B, Clinical cytometry.

[19]  G. Salles,et al.  Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center , 2020, American journal of hematology.

[20]  Y. Balagurunathan,et al.  High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.

[21]  Matthew J. Frigault,et al.  Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Stuart A. Sievers,et al.  Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T-cell therapy. , 2020, JCI insight.

[23]  J. Vose,et al.  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  F. Venet,et al.  Myeloid cells in sepsis‐acquired immunodeficiency , 2020, Annals of the New York Academy of Sciences.

[25]  T. Rimmele,et al.  Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes , 2020, Critical Care.

[26]  S. Kenderian,et al.  Myeloid cell and cytokine interactions with chimeric antigen receptor-T-cell therapy: implication for future therapies. , 2019, Current opinion in hematology.

[27]  S. Tu,et al.  Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies , 2019, Front. Immunol..

[28]  T. Fry,et al.  Mechanisms of resistance to CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[29]  S. Neelapu.  CAR-T efficacy: is conditioning the key? , 2019, Blood.

[30]  D. Maloney,et al.  The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. , 2019, Blood.

[31]  Nima Aghaeepour,et al.  How Clinical Flow Cytometry Rebooted Sepsis Immunology , 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[32]  M. Weigand,et al.  Monocyte HLA-DR Assessment by a Novel Point-of-Care Device Is Feasible for Early Identification of ICU Patients With Complicated Courses—A Proof-of-Principle Study , 2019, Front. Immunol..

[33]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.

[35]  A. Belot,et al.  Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock , 2018, Critical Care.

[36]  C. Rooney,et al.  Modeling cytokine release syndrome , 2018, Nature Medicine.

[37]  M. Sadelain,et al.  CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade , 2018, Nature Medicine.

[38]  C. Doglioni,et al.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells , 2018, Nature Medicine.

[39]  B. Min.  Spontaneous T Cell Proliferation: A Physiologic Process to Create and Maintain Homeostatic Balance and Diversity of the Immune System , 2018, Front. Immunol..

[40]  M. Gandhi,et al.  B cell lymphoma progression promotes the accumulation of circulating Ly6Clo monocytes with immunosuppressive activity , 2018, Oncoimmunology.

[41]  D. Gabrilovich,et al.  Myeloid-derived suppressor cells coming of age , 2018, Nature Immunology.

[42]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[43]  M. Sabatino,et al.  Removal Of Myeloid Cells From Autologous Leukocytes Used For Chimeric Antigen Receptor (Car) T Cell Manufacturing Improves Final Product Consistency And Yields , 2017 .

[44]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[45]  F. Venet,et al.  Sepsis‐induced immune alterations monitoring by flow cytometry as a promising tool for individualized therapy , 2016, Cytometry. Part B, Clinical cytometry.

[46]  K. Tarte,et al.  T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. , 2015, Blood.

[47]  S. H. van der Burg,et al.  Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study , 2016, Cancer Immunology, Immunotherapy.

[48]  K. English,et al.  Suppression of IL-7-dependent Effector T-cell Expansion by Multipotent Adult Progenitor Cells and PGE2. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  Zhiping Wang,et al.  Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma. , 2015, International journal of clinical and experimental medicine.

[50]  M. Mohammadnia-Afrouzi,et al.  Myeloid-derived suppressor cells in B cell malignancies , 2015, Tumor Biology.

[51]  A. Dietz,et al.  IL-10 induces the development of immunosuppressive CD14+HLA-DRlow/− monocytes in B-cell non-Hodgkin lymphoma , 2015, Blood Cancer Journal.

[52]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  A. Polliack,et al.  Absolute monocytosis at diagnosis correlates with survival in diffuse large B‐cell lymphoma—possible link with monocytic myeloid‐derived suppressor cells , 2013, Hematological oncology.

[54]  S. Singhal,et al.  Myeloid derived suppressor cells , 2013, Oncoimmunology.

[55]  J. Timsit,et al.  Inter‐laboratory assessment of flow cytometric monocyte HLA‐DR expression in clinical samples , 2013, Cytometry. Part B, Clinical cytometry.

[56]  B. Allaouchiche,et al.  Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma , 2010, Critical care.

[57]  G. Salles,et al.  Plasma TNF-α and IL-10 Level-Based Prognostic Model Predicts Outcome of Patients with Diffuse Large B-Cell Lymphoma in Different Risk Groups Defined by the International Prognostic Index , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[58]  T. Baumann,et al.  Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. , 2009, American journal of respiratory and critical care medicine.

[59]  R. Gress,et al.  T cell immune reconstitution following lymphodepletion. , 2007, Seminars in immunology.

[60]  N. Voirin,et al.  Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock , 2006, Intensive Care Medicine.

[61]  C. Meisel,et al.  Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. , 2005, Clinical chemistry.

[62]  M. Zembala,et al.  Tumor cell‐induced deactivation of human monocytes , 2003, Journal of leukocyte biology.

[63]  J. Bienvenu,et al.  Analytical requirements for measuring monocytic human lymphocyte antigen DR by flow cytometry: application to the monitoring of patients with septic shock. , 2002, Clinical chemistry.

[64]  L. Bogatzki,et al.  Naive T Cells Transiently Acquire a Memory-like Phenotype during Homeostasis-Driven Proliferation , 2000, The Journal of experimental medicine.